Saladax enters into master collaboration agreement with Bristol- Myers Squibb

Companies have already initiated a new companion diagnostic project in an undisclosed field, and deal may include multiple feasibility studies and companion diagnostic development projects

Jeffrey Bouley
BETHLEHEM, Pa.—Saladax Biomedical Inc., aprivately held company developing and commercializing novel diagnostic assaysto achieve the promise of personalized medicine for new and existingtherapeutics, recently the company has expanded its existing relationship withBristol-Myers Squibb Co. by entering into a master early developmentcollaboration agreement, which may include multiple feasibility studies andcompanion diagnostic development projects. With the signing of this agreement,the companies have already initiated a new companion diagnostic project in anundisclosed field. Terms of the agreement were not disclosed.
 
"Saladax is delighted to continue workingwith Bristol-Myers Squibb to deliver on the promise of personalizedmedicine," said Kevin M. Harter, president and CEO of Saladax."Building on our previous work together, which resulted in clinicallyvaluable Alzheimer's disease assays, we're eager to continue marrying thescientific and clinical knowledge of Bristol-Myers Squibb and Saladax toimprove the lives of patients in other clinical areas."
 
 
Saladax and Bristol-Myers Squibb originallyentered into a collaboration in 2010 for the development of clinical diagnostictests for Alzheimer's disease to be used in conjunction with the development ofcertain therapeutic compounds in the Bristol-Myers Squibb pipeline. 

SOURCE: Saladax news release
 

 

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022